MARKET

ZYME

ZYME

Zymeworks
NASDAQ
26.87
+0.01
+0.04%
Pre Market: 26.87 0 0.00% 08:05 12/29 EST
OPEN
26.87
PREV CLOSE
26.86
HIGH
26.98
LOW
26.51
VOLUME
159
TURNOVER
0
52 WEEK HIGH
28.49
52 WEEK LOW
9.03
MARKET CAP
2.01B
P/E (TTM)
-31.8063
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ZYME last week (1222-1226)?
Weekly Report · 3h ago
Weekly Report: what happened at ZYME last week (1215-1219)?
Weekly Report · 12/22 10:11
How FDA Approval of Zanidatamab in HER2 Biliary Cancer Will Impact Zymeworks (ZYME) Investors
Simply Wall St · 12/18 07:18
Zymeworks Price Target Announced at $40.00/Share by Truist Securities
Dow Jones · 12/17 12:37
Zymeworks Initiated at Buy by Truist Securities
Dow Jones · 12/17 12:37
Truist Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $40
Benzinga · 12/17 12:26
ZYMEWORKS INC <ZYME.O>: TRUIST SECURITIES INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $40
Reuters · 12/17 12:01
Zymeworks initiated with a Buy at Truist
TipRanks · 12/17 11:21
More
About ZYME
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Webull offers Zymeworks Inc stock information, including NASDAQ: ZYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYME stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZYME stock methods without spending real money on the virtual paper trading platform.